The Weight Loss Drug That Hit 28.7% — What Retatrutide Actually Is and Why It Matters Now

If you've been paying attention to the weight-loss drug space lately, you've probably seen the number 28.7% floating around without much context. That's the average body weight reduction from Eli Lilly's TRIUMPH-4 trial — a phase 3 study of a drug called retatrutide.

For reference, the most effective FDA-approved weight-loss drug currently available produces about 20% average loss. Bariatric surgery typically delivers somewhere between 25% and 35%.

So when a drug still in clinical trials hits 28.7% in a study involving real patients with obesity and knee osteoarthritis, then it's no surprise that everyone's attention is suddenly on it. What's considered possible has now been stretched beyond its limit.

But retatrutide isn't available. It's not FDA-approved. And the versions you might find being sold online with dosing instructions attached? The FDA has been issuing warning letters about those since 2025.

This article isn't about getting access to it. It's about understanding what it actually does — and why that matters for making sense of everything that's already on the market: semaglutide, tirzepatide, and the supplement decisions that sit around all of them.

We've mapped the full clinical picture so you know what's real, what's pending, and what the science actually says about how this drug class works.

What Makes Retatrutide Different From Semaglutide and Tirzepatide

To understand why retatrutide is being talked about the way it is, you need a quick map of how this drug class evolved.

Semaglutide — the active ingredient in Ozempic and Wegovy — is a GLP-1 receptor agonist. It mimics a gut hormone that suppresses appetite, slows gastric emptying, and improves glucose control. In the landmark STEP 1 trial, it produced around 15% average weight loss in people without diabetes. That was a watershed number when it came out.

Tirzepatide (Zepbound, Mounjaro) added a second target: the GIP receptor. GIP is another incretin hormone, and activating both GIP and GLP-1 together appears to produce additive effects on appetite suppression and glucose regulation. In the SURMOUNT-5 head-to-head trial, tirzepatide delivered 20.2% average weight loss versus 13.7% with semaglutide — a 47% relative difference.

Retatrutide adds a third target: the glucagon receptor.

Glucagon is the hormone that typically raises blood sugar between meals. But activating glucagon receptors in the context of a drug that's already suppressing appetite and improving glucose control appears to add something different — increased energy expenditure.

The theory is that glucagon agonism may help the body burn more energy at rest, adding a metabolic-rate component on top of the appetite suppression that GLP-1 and GIP provide.

That's the triple agonist concept. Eat less, feel full faster, and potentially burn a little more at rest — all from a single weekly injection.

What the Phase 2 Data Actually Showed

The study that put retatrutide on the map was a phase 2 trial published in the New England Journal of Medicine in 2023. It enrolled adults with obesity or overweight who didn't have diabetes.

The results at 48 weeks were striking enough to change how the field talked about what's achievable with medication. At the highest dose (12 mg), the trial showed a mean weight reduction of 24.2%. Every participant in that group lost at least 5% of their body weight. 26% lost at least 30%.

The trial also noted something that's rarely seen in drug studies: no clear plateau by the time data collection ended. Most weight-loss drugs show diminishing returns over time. The retatrutide phase 2 curve hadn't bent yet at 48 weeks.

The diabetes subgroup told a different story — meaningful weight loss, but considerably less than the non-diabetic population. This is consistent with what's seen across the entire drug class. People with type 2 diabetes typically lose less weight on these drugs than people without. It's worth knowing that guardrail before applying phase 2 headlines to any individual situation.

The Phase 3 TRIUMPH Program — Where Things Stand Now

Phase 3 is where investigational drugs either prove out across broader populations or reveal problems that smaller trials missed. Retatrutide's phase 3 program is called TRIUMPH, and it's the most ambitious registrational effort Eli Lilly has run in this class.

The TRIUMPH-4 trial, which read out in December 2025, is the most detailed public data available. It enrolled adults with obesity and knee osteoarthritis — a deliberately complex patient population. At the highest dose, participants lost 28.7% of body weight on average over 68 weeks. Knee pain scores dropped 74.3% on the WOMAC scale. Systolic blood pressure fell 14 mmHg.

The tolerability data is worth paying attention to. Discontinuation due to adverse events was 18.2% in the highest-dose group versus 4% with placebo. About 21% of the 12 mg group experienced dysesthesia — an unusual neurological side effect involving altered skin sensation that's relatively specific to retatrutide and not typically seen with semaglutide or tirzepatide.

Seven additional phase 3 readouts are expected across 2026, covering the primary obesity population, a type 2 diabetes cohort, a cardiovascular outcomes trial, a head-to-head comparison against tirzepatide, and a weight maintenance study.

Why Retatrutide Isn't Available — and What "Not FDA-Approved" Actually Means

Retatrutide cannot be legally prescribed in the United States today. It is not part of any approved new drug application. Outside of clinical trials, there is no legitimate way to obtain it.

This matters because there's a market for compounded versions that claim to contain retatrutide. The FDA has issued warning letters specifically about these products, describing them as unapproved new drugs and misbranded when introduced into interstate commerce. The warning language is unusually direct: these products present unknown quality and may cause harm.

The distinction between "unapproved" and "unsafe" is worth being careful about. It doesn't mean retatrutide is dangerous — the clinical trial data shows a known, manageable side effect profile for people in supervised studies with appropriate screening and titration.

What it means is that a compounded product sitting outside that infrastructure has no verified purity, no validated dosing, and no medical oversight catching problems early.

Estimated approval timeline, based on current trial schedules and standard FDA review: late 2026 to early 2027 if phase 3 results hold. That's not a guarantee — regulatory timelines shift — but it gives a frame.

How the Body Composition Data Should Change Your Expectations

One of the under-covered angles across this entire drug class is what happens to lean mass — muscle — during rapid weight loss.

The TRIUMPH-4 body composition substudy showed that roughly two-thirds of the tissue lost on retatrutide was fat, with about one-third lean mass. That ratio is consistent with tirzepatide's body composition data from SURMOUNT-1, where approximately 25% of total weight lost came from lean tissue.

For the average person thinking about GLP-1 therapy, this means the number on the scale tells an incomplete story. Losing 20% of body weight while losing significant muscle mass has different long-term consequences than losing the same amount predominantly as fat.

This is why the protein, creatine, and resistance training conversation has become inseparable from the drug conversation. The clinical data doesn't exist in isolation — it's pointing directly at what the supplement and lifestyle protocol needs to do.

What This Means for People Already on Semaglutide or Tirzepatide

Most people reading this aren't in a clinical trial. They're on Wegovy or Zepbound, or thinking about starting one of those drugs, or on a compounded version from a telehealth provider. Retatrutide doesn't change their situation directly.

What it does do is sharpen the case for taking the support protocol seriously.

If a drug producing 15–20% weight loss still pulls about a quarter of that from lean tissue, then every percentage point of weight loss carries a muscle cost. Protein intake at 1.2–2.0g per kilogram of body weight daily, resistance training 2–3 times per week, and creatine supplementation all have direct clinical support for reducing that lean mass loss. None of those things change while you're waiting for a new drug.

For practical next steps, our GLP-1 supplement guide covers the full stack — including which protein powders work well when appetite is suppressed and which micronutrient gaps show up most consistently in people on these medications.

If muscle preservation is your priority, the best protein powders for GLP-1s guide goes deeper on the whey vs plant protein question in the context of nausea and reduced appetite.

How semaglutide, tirzepatide, and retatrutide sit relative to each other — mechanistically and by efficacy — is covered directly in our three-generation peptide comparison. And if you're already on a GLP-1 and wondering what happens if you stop, we broke down the discontinuation data in stopping a GLP-1 medication.

Your prescriber is the right person to evaluate whether any of these drugs are appropriate for your specific situation. What we can do is make sure you go into that conversation understanding what the clinical data actually says.